Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.58 USD | -0.75% | -4.15% | -6.00% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.00% | 18.67M | |
+38.01% | 705B | |
+32.82% | 583B | |
-3.64% | 364B | |
+20.15% | 332B | |
+5.19% | 291B | |
+17.25% | 238B | |
-3.64% | 210B | |
+10.47% | 209B | |
+8.53% | 169B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Wedbush Lowers Kala Pharmaceuticals' Price Target to $6 From $16 on 'Persisting Issues' Affecting Inveltys, Eysuvis Launches; Outperform Rating Kept